Bayer has signed definitive agreements to acquire AT-01 and AT-05, two investigational molecular imaging agents for cardiac amyloidosis, from Attralus.
The move signals Bayer’s formal entry into diagnostic tracers and reinforces its expansion in molecular imaging.
The acquisition includes two complementary imaging agents targeting cardiac amyloidosis.
Financial terms were not disclosed.
Cardiac amyloidosis is rare, underdiagnosed, and often fatal. Key challenges include:
An estimated 400,000 people globally are affected.
AT-01 is a non-invasive pan-amyloid PET imaging agent. It can detect multiple amyloid types, including:
Deposits are identified across organs such as:
AT-01 is:
The Phase 3 REVEAL study has completed dosing.
AT-05 uses SPECT imaging, a more widely available modality. This could:
The agent is currently in Phase 1 development.
The acquisition aligns with Bayer’s push toward precision cardiology.
Bayer brings:
The company already markets Beyonttra (acoramidis) for ATTR cardiomyopathy.
The global radio-diagnostic tracer market was valued at $3 billion in 2024.
Strong growth is expected, driven by:
Bayer aims to deliver end-to-end solutions, from diagnosis to care.
With the transaction completed, Attralus will refocus on therapeutics. Its pipeline includes:
The deal enables sharper focus on disease-modifying treatments.
Bayer’s acquisition of AT-01 and AT-05 marks a decisive step into molecular diagnostics.
By combining imaging innovation with cardiology expertise, Bayer is positioning itself to change how cardiac amyloidosis is detected and managed.